Vimizim
Named-patient access overview. Vimizim is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Vimizim (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase enzyme replacement therapy manufactured by BioMarin Pharmaceutical. The drug was approved by the US Food and Drug Administration in February 2014 for the treatment of Morquio A syndrome, also known as mucopolysaccharidosis type IVA (MPS IVA), a rare autosomal recessive lysosomal storage disorder caused by deficiency of the GALNS enzyme.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Vimizim
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Vimizim is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Vimizim in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Vimizim
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.